|
시장보고서
상품코드
2075305
파킨슨병 치료제 시장 : 약물 계열별, 투여 경로별, 유통 채널별, 지역별Parkinsons Disease Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
파킨슨병 치료제 시장은 2026년에 62억 7,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 102억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.2%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 62억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 7.20% | 2033년 시장 규모 예측: | 102억 달러 |
파킨슨병은 신경학적 질환으로 인해 발생하는 운동 장애입니다. 떨림, 동작 둔화, 근육 경직, 보행 불안정, 균형 감각 및 협응력 장애 등이 일반적인 증상으로 꼽힙니다. 레보도파, 도파민 작용제, MAO-B 억제제, 항콜린제 등은 파킨슨병 치료에 사용되는 약물의 일부입니다. 레보도파(L-도파라고도 함)는 파킨슨병 치료에 가장 흔히 처방되는 약물입니다. 운동 지연이나 몸의 뻣뻣함·경직과 같은 증상을 조절하는 데 효과적입니다. 약물 치료를 통해 대다수의 환자는 높은 삶의 질을 유지할 수 있으며, 수술을 통해 증상이 호전되는 경우도 있습니다. 파킨슨병 환자의 경우, 노르에피네프린이라고 불리는 또 다른 신경전달물질의 감소도 관찰됩니다. 이 분자는 교감신경계가 정상적으로 기능하는 데 필요합니다. 소화, 심박수, 혈압, 호흡 등 체내 자율신경에 의한 활동의 일부는 이 시스템에 의해 조절됩니다. 파킨슨병의 운동 증상 이외의 일부 증상은 노르에피네프린 결핍으로 인해 발생합니다. 운동은 파킨슨병의 증상을 크게 개선할 수 있습니다. 물리치료, 작업치료, 언어청각치료도 보행 및 균형 문제, 식사 및 연하 곤란, 언어 장애의 개선에 도움이 됩니다.
시장 역학
시장에 진출한 각 기업은 신제품 출시에 주력하고 있으며, 이는 예측 기간 동안 파킨슨병 치료제 시장의 성장을 견인할 것으로 전망됩니다. 예를 들어, 2020년 5월, 제약회사인 Sunovion Pharmaceuticals Inc.는 파킨슨병 환자의 ‘OFF 에피소드’(즉, 파킨슨병 증상의 재발 또는 악화)에 대한 급성 및 간헐적 치료를 목적으로 하는 ‘KYNMOBI(아포모르핀 염산염) 설하 필름’에 대해 미국 식품의약국(FDA)으로부터 승인을 획득했다고 발표했습니다. KYNMOBI에는 10mg, 15mg, 20mg, 25mg 등 다양한 용량이 준비되어 있습니다.
이 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 파라미터(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 파킨슨병 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- '세계 파킨슨병 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 파킨슨병 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 파킨슨병 치료제 시장 : 약물 계열별
제5장 세계의 파킨슨병 치료제 시장 : 투여 경로별
제6장 세계의 파킨슨병 치료제 시장 : 유통 채널별
제7장 세계의 파킨슨병 치료제 시장 : 지역별
제8장 경쟁 구도
제9장 섹션
KSM 26.07.09Parkinsons Disease Therapeutics Market is estimated to be valued at USD 6.27 Bn in 2026 and is expected to reach USD 10.20 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.27 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.20% | 2033 Value Projection: | USD 10.20 Bn |
Parkinson's disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms. Levodopa, Dopamine agonists, MAO-B inhibitors, and Anticholinergics are some of the medications used for the treatment of Parkinson's disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson's disease. It is useful in controlling the symptoms such as slow movements and stiff & rigid body parts. Medication allows the majority of patients to retain a high quality of life and surgery can help some people improve their symptoms. Parkinson's disease patients also observe decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.
Market Dynamics
Market players are focusing on new product launches, which is expected to propel the Parkinson's disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc. a pharmaceutical company announced that it received the U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) Sublingual Film for the acute, intermittent treatment for OFF episodes (i.e. re-emergence or worsening of PD symptoms) in patients with Parkinson's disease. KYNMOBI is available in different strengths such as 10mg, 15mg, 20mg, and 25mg.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Parkinson's disease therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Parkinson's disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global Parkinson's disease therapeutic market
Detailed Segmentation:
- Global Parkinson's Disease Therapeutic Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Global Parkinson's Disease Therapeutic Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- Global Parkinson's Disease Therapeutic Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Parkinson's Disease Therapeutic Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Levodopa
- By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Drug Class
- Latin America
- By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Levodopa
- By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class
- Europe
- By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Levodopa
- By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drug Class
- Asia Pacific
- By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Levodopa
- By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Class
- Middle East
- By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Levodopa
- By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- By Drug Class
- Africa
- By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
- Levodopa
- By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Drug Class
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4 Global Parkinsons Disease Therapeutics Market, By Drug Class, 2021- 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Levodopa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Dopamine agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- MAO-B inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Anticholinergics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
5 Global Parkinsons Disease Therapeutics Market, By Route of Administration, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
- Others (Rectal, Sublingual, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
6 Global Parkinsons Disease Therapeutics Market, By Distribution Channel, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
7 Global Parkinsons Disease Therapeutics Market, By Region, 2021-2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- 'Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 -2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8 Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Dr. Reddy's Laboratories
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Denali Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biogen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Prevail Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Voyager Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd.*
9 Section
- References
- Research Methodology
- About us and Sales Contact
